The honest bottom line is that GHRP-2, also documented as pralmorelin, is treated as an unapproved investigational peptide rather than a licensed medicine, with no Food and Drug Administration approval as either a drug or a dietary ingredient. Its status is not fixed: it shifts with the specific use, the country, and whether sport-governance rules apply, which is why the same compound can read as a gray-market reagent in one context and a prohibited substance in another.
GHRP-2 is legally an unapproved investigational peptide with no FDA approval as a drug or dietary ingredient, and its consequences turn on the specific use, the country, and whether anti-doping rules apply.
GHRP-2 is a synthetic hexapeptide in the growth hormone secretagogue class, and more precisely a ghrelin receptor agonist. What draws regulatory and anti-doping attention is mechanical: it binds the growth hormone secretagogue receptor on the pituitary and hypothalamus and prompts a pulse of the body's own growth hormone, so regulators treat it as pharmacologically active rather than an inert chemical.
GHRP-2, also recorded as pralmorelin and development code KP-102, is a six-amino-acid ghrelin receptor agonist that raises endogenous growth hormone rather than supplying the hormone itself.
The single most important fact about GHRP-2's status is that it carries no FDA marketing approval for any therapeutic use. It has never cleared the new-drug approval process, so there is no approved labeling, no approved indication, and no recognized safe-and-effective use, and it is separately not a lawful dietary supplement ingredient, which leaves it in the category of an unapproved new drug.
GHRP-2 holds no FDA approval for any indication and does not qualify as a dietary ingredient, placing it in the unapproved-new-drug category that cannot lawfully be sold for human use.
The research-chemical and not-for-human-consumption labels exist to move a product out of the categories regulators police most heavily, not to grant the buyer permission. Framing a vial as a laboratory reagent sidesteps the drug-approval and supplement rules a human-use sale would trigger, but regulators generally look past the sticker to the real intended use, and the wording does nothing for purity or safety.
| Aspect | What the label implies | Regulatory and quality reality |
|---|---|---|
| Legality | Permitted reagent sale | Shields the seller, not the buyer; intended human use stays unlawful |
| Safety | Product is acceptable to use | No permission to inject is granted or implied |
| Purity and identity | Implicitly adequate | Not made to pharmaceutical standards; content, sterility, and identity vary by batch |
The research-use-only label is a disclaimer that limits the seller's exposure, not a grant of legal permission, and it offers no guarantee of purity, sterility, or correct peptide content.
There is no single worldwide legal status for GHRP-2, and that variation is the defining feature of its international picture. Because it is an unapproved peptide rather than a globally scheduled narcotic, each country files it under whichever existing framework fits, and those frameworks run from prescription-only medicine to lightly watched laboratory chemical.
The same vial of GHRP-2 can be a border seizure, a prescription-only medicine, or a lightly watched reagent depending entirely on the jurisdiction, because each country slots it into its existing framework rather than a shared global schedule.
A legitimate prescription route for GHRP-2 exists only in narrow and shrinking circumstances, and it looks nothing like buying research chemicals online. Compounding is restricted to approved drug ingredients or substances on a permitted list, and recent regulatory tightening has specifically narrowed the set of peptides a pharmacy may lawfully prepare, closing options that once seemed open.
A lawful compounding route for GHRP-2 requires an individualized prescription, a state-licensed and inspected pharmacy, and documented sourcing, and regulatory tightening has narrowed which peptides qualify, so most circulating material never passes through it.
The legal exposure around GHRP-2 rises steadily as conduct moves from simply holding a vial toward importing, using, and distributing it. The gray-market supply chain underneath all of it is unregulated and opaque, so the seller, the contents, and the legality of a given transaction often cannot be verified, and that uncertainty is itself a form of legal risk.
Legal exposure to GHRP-2 escalates from customs seizure of imports, to loss of the research-use cover once human use is evident, to active enforcement against distribution, with licensed professionals separately facing disciplinary action from their credentialing boards.
Setting GHRP-2 beside recombinant human growth hormone makes its position on the regulatory ladder easy to read. Approved growth hormone is a licensed medicine with defined indications, verified identity and potency, and prescriber-monitored use, while GHRP-2 acting on the same growth hormone axis carries none of those guarantees when it circulates as a research chemical.
| Criteria | Recombinant human growth hormone | GHRP-2 |
|---|---|---|
| Approval | Approved for defined indications | No approved indication |
| Manufacturing | Pharmaceutical standard, verified identity and potency | No oversight as a research chemical |
| Access | Prescription and controlled distribution | Largely an unregulated market |
| Sport status | Prohibited by the anti-doping code | Prohibited by the anti-doping code |
Recombinant human growth hormone is an approved medicine manufactured to pharmaceutical standards and dispensed by prescription, whereas GHRP-2 has no approved indication, no manufacturing oversight, and moves largely through an unregulated market, though anti-doping authorities prohibit both.
Educational use only. This article describes what the published scientific and clinical literature reports about GHRP-2. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
